arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

ALNYLAM PHARMACEUTICALS, INC.

ALNY
$156.31 ▼ -4.69 (-2.92%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
73 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Bullish
auto_awesome

Analytical Summary

ALNYLAM PHARMACEUTICALS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $20.9B
Dividend Yield —
Revenue Growth 16.7% ↘
Op. Margin 23.7% ↗
ROIC 70.3% ↗
FCF / Share $2.03
Trailing P/E 9.7x
Price / Book 5.8x
FCF Yield 1.3%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

73-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.46B
↑ +16.7% —
Net Income Profit after all expenses
$205.99M
— 0.0% —
Operating Margin Operating profit as % of sales
23.7%
↑ +32.3% 64th
FCF / Share Free cash flow per share
$2.03
↑ +306.4% —
Long-Term Debt Long-term obligations
$677.72M
— +0.1% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
64
Returns
95
Financial Health
61
Cash Quality ↑
79

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 73 quarters